Offers fair pricing

5 campaigns on this issue

• Interfaith Center on Corporate Responsibility members at six drugmakers on patents and access, 2024
  Trinity Health · AbbVie, Eli Lilly, Gilead Sciences · 2024 · Not approved where it reached a vote. AbbVie, 3 May 2024: 315,426,248 for, 941,651,498 against, 17,953,817 abstaining and 245,929,517 broker non-votes. Eli Lilly, 6 May 2024: 68,370,561 for, 699,538,270 against, 6,506,288 abstaining and 82,256,109 broker non-votes. At the other four companies it did not reach a vote.
• Oxfam America at Moderna, Pfizer and Johnson & Johnson on COVID-19 vaccine access
  Oxfam America · Moderna, Pfizer Inc., Johnson & Johnson · 2022 · All three proposals were voted down at meetings held on 28 April 2022. Moderna's Proposal 4 drew 70,878,392 votes for and 227,007,857 against, with 1,518,730 abstentions and 34,671,090 broker non-votes, which is 23.8% of the votes cast for and against. Pfizer's Item 6 drew 1,023,141,083 for and 2,714,524,824 against, or 27.4%. Johnson & Johnson's Item 8 drew 616,715,019 for and 1,207,732,861 against, or 33.8%. Oxfam put the Moderna figure at 24 percent of the nominal vote and 29 percent of the independent vote, once the 17 percent held by the company's directors and senior executives is set aside, and said it was the first time shareholders had voted for a resolution of this kind on any company proxy ballot.
• Mercy Investment Services and United Church Funds at five drugmakers on drug pricing in executive pay, 2020
  Mercy Investment Services · AbbVie, Amgen, Biogen · 2019 · Filed on 14 November 2019 for the 2020 proxy season at AbbVie, Amgen, Biogen, Eli Lilly and Pfizer, with Mercy Investment Services lead filer at Amgen and Eli Lilly and United Church Funds leading the engagement with AbbVie. It reached a vote at two of the five. AbbVie, 8 May 2020: not approved, 249,382,082 for, 773,211,511 against, 19,752,693 abstaining and 251,100,201 broker non-votes, or 24.4 percent of the votes cast for and against. Eli Lilly, 4 May 2020: not approved, 184,652,906 for, 570,094,648 against, 27,534,077 abstaining and 83,997,305 broker non-votes, or 24.5 percent. No proposal on drug pricing and executive pay appears in the certified results of Amgen's meeting on 19 May 2020, Biogen's on 3 June 2020 or Pfizer's on 23 April 2020.
• United Church Funds and ICCR members at AbbVie on drug pricing risk in executive pay, 2018
  United Church Funds · AbbVie · 2018 · Not approved at the 4 May 2018 annual meeting: 247,879,964 for, 887,590,325 against, 14,559,605 abstaining and 260,703,800 broker non-votes, which is 21.8 percent of the votes cast for and against. It was a first-time proposal, it survived AbbVie's attempt at the SEC to have it omitted from the proxy, and the proxy adviser ISS recommended a vote for it.
• Michael Weinstein at Gilead Sciences on tying CEO pay to patient access, 2014
  Michael Weinstein, an individual shareholder · Gilead Sciences · 2014 · Not approved at the 7 May 2014 annual meeting as Proposal 7: 26,726,195 for, 1,048,057,432 against, 157,155,528 abstaining and 115,351,928 broker non-votes, which is 2.5 percent of the votes cast for and against.

Organizations working on this